NATIMMUNE AS has a total of 33 patent applications. Its first patent ever was published in 2001. It filed its patents most often in WIPO (World Intellectual Property Organization), China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and computer technology are ZYMOGENETICS L L C, BIO DISCOVERY LTD and PROTAGONIST THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 10 | |
#2 | China | 9 | |
#3 | EPO (European Patent Office) | 8 | |
#4 | United States | 3 | |
#5 | Australia | 2 | |
#6 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Computer technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Bioinformatics |
# | Name | Total Patents |
---|---|---|
#1 | Matthiesen Finn | 9 |
#2 | Kongerslev Leif | 7 |
#3 | Weilguny Dietmar | 3 |
#4 | Agger Teit | 3 |
#5 | Larsen Jesper Lund | 3 |
#6 | Fischer Per | 3 |
#7 | Finn Matthiesen | 3 |
#8 | Ruffet Emmanuel | 2 |
#9 | Zavodsky Peter | 2 |
#10 | Ambrus Geza | 2 |
Publication | Filing date | Title |
---|---|---|
WO2009003489A1 | CaOU-1 EPITOPE BINDING POLYPEPTIDES | |
WO2008064686A1 | Methods of separating nucleic acids and protein | |
CN101193651A | Mannan-binding lectin (MBL) in the treatment of immunocompromised conditions asssociated with cancer | |
WO2005024013A1 | Masp-2 crystal structure and uses thereof | |
CN1878862A | MASP-2 crystal structure and uses thereof | |
CN1805753A | Treatment of severe acute respiratory syndrome (SARS) | |
CN1694961A | Collectin-complement activating protein chimeras | |
WO03077937A1 | Pharmaceutical compositions comprising mannose binding lectin | |
CN1599747A | Isolation of lectins | |
CN101011573A | Production of high molecular mass lectins | |
AU7841601A | Mannan-binding lectin (mbl) treatment of infections in individuals treated with tnf-alphainhibitors |